Core Insights - Several healthcare and biotech companies experienced significant stock price increases due to clinical updates, earnings results, and regulatory developments Company Summaries - Sensei Biotherapeutics Inc. (SNSE) saw a 62.9% increase to $17.20 after hours, following a 21.4% rise at the close. The company reported a narrower third-quarter net loss of $4.6 million compared to $7.3 million a year earlier, ending September with $25.0 million in cash and equivalents, down from $41.3 million at the end of 2024 [2] - Praxis Precision Medicines, Inc. (PRAX) advanced 24.8% to $237.10 after positive results from the EMBOLD study on relutrigine. The Data Monitoring Committee recommended stopping the study early for efficacy, and the company is targeting an NDA filing in early 2026 after aligning with the FDA [3] - The CooperCompanies, Inc. (COO) climbed 13.0% to $87.01, reporting fourth-quarter net income of $84.6 million, or $0.43 per share, down from $117.5 million, or $0.58 per share, last year. Revenue rose 4.6% to $1.065 billion, and the company issued guidance for first-quarter EPS of $1.02-$1.04 and revenue of $1.019-$1.030 billion [4] - Vanda Pharmaceuticals Inc. (VNDA) gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on protocol VP-VLY-686-3403, allowing for increased dosing of tradipitant [5] - Cue Biopharma, Inc. (CUE) rose 7.8% to $0.60 after an exclusive in-licensing deal with ImmunoScape to advance Immuno-STAT molecules in oncology [6]

Core Insights - The Cooper Companies reported revenue of $1.07 billion for the quarter ended October 2025, reflecting a year-over-year increase of 4.6% and an EPS of $1.15, up from $1.04 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.06 billion, resulting in a surprise of +0.45%, while the EPS also surpassed expectations by +3.6% [1] Financial Performance - Revenue by Geography: - Americas: $285.1 million, a +5.4% change year-over-year, but below the estimated $291.49 million [4] - Asia Pacific: $147.4 million, a -1.3% change year-over-year, exceeding the estimated $139.8 million [4] - EMEA: $277.1 million, an +8% change year-over-year, above the estimated $269.49 million [4] - Revenue by Category: - CVI: $709.6 million, a +4.9% change year-over-year, slightly above the estimated $707.83 million [4] - CSI: $355 million, a +3.8% change year-over-year, exceeding the estimated $352.65 million [4] - CSI- Office and surgical: $214.6 million, a +5.8% change year-over-year, above the estimated $208.89 million [4] - CSI- Fertility: $141 million, a +1.3% change year-over-year, below the estimated $144.03 million [4] - CVI- Sphere, other: $365 million, a +3.3% change year-over-year, above the estimated $362.34 million [4] - CVI- Toric and multifocal: $344.6 million, a +6.6% change year-over-year, slightly below the estimated $346.45 million [4] Stock Performance - The Cooper Companies' shares have returned +10.3% over the past month, significantly outperforming the Zacks S&P 500 composite, which changed by +0.1% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]

分组1 - The Cooper Companies reported quarterly earnings of $1.15 per share, exceeding the Zacks Consensus Estimate of $1.11 per share, and showing an increase from $1.04 per share a year ago, resulting in an earnings surprise of +3.60% [1] - The company achieved revenues of $1.07 billion for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 0.45%, and up from $1.02 billion in the same quarter last year [2] - Over the last four quarters, The Cooper Companies has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] 分组2 - The stock has underperformed the market, losing about 17.4% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is $1.00 on revenues of $1.03 billion, and for the current fiscal year, it is $4.38 on revenues of $4.31 billion [7] - The Medical - Dental Supplies industry, to which The Cooper Companies belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - Consolidated revenues increased by 4.6% year over year, reaching a record of $1.065 billion, with organic growth of 3.4% [9][19] - Non-GAAP earnings per share (EPS) grew by 11% to $1.15, marking the eighth consecutive quarter of beating consensus earnings expectations [7][19] - Free cash flow for Q4 was reported at $150 million, exceeding expectations, with a target of over $2.2 billion in free cash flow from fiscal 2026 to 2028 [7][23] Business Line Data and Key Metrics Changes - CooperVision reported revenue of $710 million, up 4.9% year over year, with organic growth of 3.2% [10][19] - CooperSurgical achieved quarterly revenue of $356 million, up 4% or 3.9% organically, driven by solid execution [14][19] - MyDay lenses showed strong growth, particularly in toric and multifocal categories, while clariti lenses experienced a decline of approximately 2% [10][28] Market Data and Key Metrics Changes - The Americas region grew by 5%, driven by daily silicone hydrogel lenses, while EMEA grew by 3% [11] - Asia-Pacific remained flat, with a significant 28% decline in China attributed to weakness in low-margin e-commerce channels [11][50] - The overall contact lens market is trending towards premium offerings, benefiting the MyDay portfolio [10][11] Company Strategy and Development Direction - The company is focused on consistent market share gains for CooperVision, with an emphasis on the MyDay Premium Daily Silicone Hydrogel Lens portfolio [6][9] - A strategic review has been initiated to explore opportunities for unlocking long-term shareholder value, including potential separation of business units [9][38][79] - The board has authorized an increase in the share repurchase plan to $2 billion, reinforcing the commitment to returning capital to shareholders [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about fiscal 2026, expecting strong revenue growth driven by MyDay sales and new private label contracts [17][53] - The company anticipates a conservative approach to guidance, particularly in the fertility segment, while remaining optimistic about long-term growth in that market [15][56] - Management highlighted the importance of maintaining fiscal responsibility and not chasing revenues at all costs, particularly in challenging markets like China [50][51] Other Important Information - The company has successfully remediated material weaknesses related to IT controls from fiscal 2024 [24] - Significant cost savings from recent reorganization efforts are expected to enhance profitability and cash flow [20][23] Q&A Session Summary Question: Clariti product line performance - Clariti was down a couple of percent this quarter, approaching $400 million in annualized revenue, with ongoing efforts to reposition the product [27][28] Question: Strategic review timeline and thoughts on separation - A strategic review is underway, with updates expected in the next earnings call, and management's position on potential separation remains unchanged [37][38][41] Question: Market growth assumptions for 2026 - The market is expected to grow at 4%-5%, with pricing power anticipated to remain stable [43][45] Question: Asia-Pacific market dynamics - Asia-Pacific faced challenges due to low-margin e-commerce channels, but management expects less detriment in fiscal 2026 [49][50] Question: Free cash flow outlook - The increase in free cash flow is driven by consistent performance and reduced capital expenditures, with expectations of over $2.2 billion in free cash flow from fiscal 2026 to 2028 [56][59] Question: Product pipeline and innovation - The company is excited about upcoming product launches, including MyDay and MiSight, which are expected to drive growth [90][91]

Financial Data and Key Metrics Changes - Consolidated revenues increased by 4.6% year over year, reaching a record of $1.065 billion, with organic growth of 3.4% [8][18] - Non-GAAP earnings per share (EPS) grew by 11% to $1.15, marking the eighth consecutive quarter of beating consensus earnings expectations [5][18] - Free cash flow for Q4 was strong at $150 million, with a total fiscal year repurchase of nearly $300 million, representing about two-thirds of free cash flow [5][19] Business Line Data and Key Metrics Changes - CooperVision reported revenue of $710 million, up 4.9% year over year, with organic growth of 3.2%, driven by improved availability of MyDay lenses [9][10] - CooperSurgical achieved quarterly revenue of $356 million, up 4% or 3.9% organically, with growth in fertility and surgical segments [14][15] Market Data and Key Metrics Changes - The Americas region grew by 5%, while EMEA grew by 3%, slightly below expectations due to market weakness in some countries [10][14] - Asia-Pacific was flat, primarily due to a 28% decline in China, attributed to weakness in low-margin e-commerce channels [10][12] Company Strategy and Development Direction - The company is focused on delivering consistent market share gains for CooperVision, with an emphasis on the MyDay Premium Daily Silicone Hydrogel Lens portfolio [4][6] - A formal strategic review has been initiated to explore opportunities for unlocking long-term shareholder value, including potential separation of business units [8][31][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about fiscal 2026, expecting strong revenue growth driven by MyDay sales and new private label contracts [39][60] - The company anticipates a conservative approach to guidance, particularly in the fertility segment, while remaining optimistic about long-term growth prospects [15][60] Other Important Information - The board authorized an increase in the share repurchase plan to $2 billion, reinforcing the commitment to returning capital to shareholders [6][19] - The company has successfully remediated material weaknesses related to IT controls from fiscal 2024 [24] Q&A Session Summary Question: Clariti product line performance - Clariti was down a couple of percent this quarter, approaching $400 million in annualized revenue, with ongoing efforts to reposition the product line [25][26] Question: Strategic review process - A strategic review is underway, with updates expected in the next earnings call, focusing on driving long-term shareholder value [30][31] Question: Market growth assumptions - The market is expected to grow at 4%-5% in fiscal 2026, with pricing power remaining stable [33][34] Question: Asia-Pacific market dynamics - The company faced challenges in Asia-Pacific, particularly in low-margin e-commerce channels, but expects less detriment in fiscal 2026 [37][38] Question: Free cash flow outlook - The increase in free cash flow is attributed to consistent performance and reduced capital expenditures, with expectations of over $2.2 billion in free cash flow from fiscal 2026 to 2028 [23][42] Question: Paragard product expectations - Guidance for Paragard includes conservatism due to potential competitive launches, with expectations for flat to low single-digit growth [55] Question: Pipeline and product launches - The company is excited about upcoming product launches, including MyDay and MiSight, which are expected to drive growth [58][59]

CooperCompanies | | | | FY26 Guidance | Q1 2026 Guidance | | --- | --- | --- | --- | --- | | | Total | $4,299 - | $4,338 | $1,019 - $1,030 | | | | (4.5% - | 5.5% organic growth) | (3% - 4% organic growth) | | e | | | | | | u n e | CooperVision | $2,900 - | $2,925 | $693 - $700 | | v | | (4.5% - | 5.5% organic growth) | (3.5% - 4.5% organic growth) | | e R | | | | | | | CooperSurgical | $1,399 - | $1,413 | $327 - $330 | | | | (4% - | 5% organic growth) | (2% - 3% organic growth) | | P | | | | | | A A | EPS | ...

Revenue Performance - Fourth quarter 2025 revenue reached $1,065.2 million, a 5% increase year-over-year, with organic growth of 3%[3] - Fiscal year 2025 revenue totaled $4.1 billion, up 5% from fiscal 2024, with organic growth of 4%[11] - Fiscal first quarter 2026 revenue guidance is set between $1,019 million and $1,030 million, with organic growth projected at 3% to 4%[13] - Fiscal 2026 total revenue guidance is between $4,299 million and $4,338 million, with organic growth of 4.5% to 5.5%[13] - Total net sales for the three months ended October 31, 2025, were $1,065.2 million, representing a 5% year-over-year increase from $1,018.4 million in the same period of 2024[49] - CooperVision's net sales for the fourth quarter of 2025 were $709.6 million, with an organic growth rate of 3%[51] - CooperSurgical's net sales for the fourth quarter of 2025 were $355.6 million, also reflecting an organic growth rate of 4%[51] Earnings and Profitability - Fourth quarter 2025 non-GAAP diluted EPS was $1.15, an 11% increase year-over-year, while GAAP diluted EPS was $0.43, down 27%[3] - GAAP net income for the three months ended October 31, 2025, was $84.6 million, with an EPS of $0.43, compared to $117.5 million and $0.58 EPS for the same period in 2024, representing a decrease of 28.0% in net income[25] - Non-GAAP net income for the twelve months ended October 31, 2025, was $826.5 million, with an EPS of $4.13, compared to $740.5 million and $3.69 EPS for the same period in 2024, indicating an increase of 11.6% in net income[25] - The company reported a net income of $374.9 million for the year ended October 31, 2025, down from $392.3 million in 2024, a decrease of about 4.3%[49] - Diluted earnings per share for the year ended October 31, 2025, were $1.87, compared to $1.96 in 2024, representing a decline of approximately 4.6%[49] - Gross profit for the year ended October 31, 2025, was $2,682.1 million, up from $2,595.7 million in 2024, indicating a growth of approximately 3.4%[49] Share Repurchase and Cash Flow - The company repurchased $197.3 million of common stock in Q4 2025, with a total of $290.1 million repurchased for the fiscal year[13] - The Board of Directors expanded the share repurchase program by $1 billion, bringing total authorization to $2 billion[13] - The company expects free cash flow to exceed $2.2 billion from 2026 to 2028, supporting share repurchases and strategic investments[2] Charges and Expenses - Total charges related to acquisition and integration for the three months ended October 31, 2025, amounted to $15.7 million, compared to $7.2 million in the same period of 2024, reflecting a 118.1% increase[25] - The company incurred $24.6 million in exit of business charges for the three months ended October 31, 2025, while no such charges were recorded in the same period of 2024[25] - The company reported a total of $451.6 million in total charges for the twelve months ended October 31, 2025, compared to $348.2 million in 2024, marking a 29.7% increase[25] - Research and development expenses for the year ended October 31, 2025, totaled $172.2 million, compared to $155.1 million in 2024, reflecting an increase of 11%[49] Market Presence and Future Outlook - The company is focused on expanding its market presence through acquisitions, specifically mentioning the obp Surgical and Cook Medical integration efforts[28] - Future guidance for fiscal year 2026 includes anticipated growth in revenues and expected savings from ongoing reorganization activities[40] - The company has a workforce of over 15,000 and sells products in over 130 countries, positively impacting over fifty million lives each year[39] Balance Sheet - Total assets as of October 31, 2025, were $12,394.8 million, a slight increase from $12,315.2 million as of October 31, 2024[47] - Total liabilities decreased to $4,155.7 million as of October 31, 2025, from $4,231.6 million in 2024, a reduction of about 1.8%[47] Other Considerations - The company emphasized the importance of ongoing research and development activities and the potential impact of environmental regulations on future operations[43]

Core Viewpoint - Cooper Companies is initiating a formal strategic review to identify opportunities for enhancing long-term shareholder value, resulting in an 11.7% increase in shares during extended trading [1] Group 1 - The strategic review aims to enhance long-term shareholder value [1] - The announcement led to a significant increase in the company's share price by 11.7% in after-hours trading [1]

Core Points - CooperCompanies has appointed Colleen Jay as the new Chair of the Board, effective January 2, 2026, succeeding Robert Weiss, who will remain on the Board for reelection [1][2] - The company is undergoing a formal strategic review to identify opportunities for enhancing long-term shareholder value [1][4] Leadership Changes - Colleen Jay has been on the Board since 2016 and has a strong background in global operational leadership, having retired from Procter & Gamble in 2017 after 32 years [2] - Robert Weiss has been a significant figure in CooperCompanies' success for nearly five decades, serving in various leadership roles including CEO from 2007 to 2018 [3] Strategic Review - The strategic review aims to improve performance in core markets, expand market share, enhance operational efficiency, and generate strong returns through disciplined capital deployment [4] - The company plans to focus on share repurchases under a $2 billion share repurchase program during this review period [4] Company Overview - CooperCompanies operates in the medical device sector with two main business units: CooperVision, a leader in the contact lens industry, and CooperSurgical, focused on fertility and women's healthcare [5] - The company has a workforce of over 15,000 and sells products in more than 130 countries, positively impacting over 50 million lives annually [5]

Core Insights - CooperCompanies reported strong financial results for fiscal year 2025, exceeding consensus expectations for revenue, earnings, and free cash flow, with a focus on long-term shareholder value through growth and profitability initiatives [2][5]. Financial Performance - Fourth quarter revenue reached $1,065.2 million, a 5% increase year-over-year, with organic growth of 3% [5][6]. - Fiscal year 2025 revenue totaled $4.1 billion, also up 5% from the previous year, with organic growth of 4% [5][13]. - GAAP diluted earnings per share (EPS) for Q4 was $0.43, down 27%, while fiscal year GAAP diluted EPS was $1.87, down 4% [5][27]. - Non-GAAP diluted EPS for Q4 was $1.15, up 11%, and for the fiscal year, it was $4.13, up 12% [5][27]. Segment Performance - CooperVision (CVI) revenue for Q4 was $709.6 million, a 5% increase year-over-year, with organic growth of 3% [6][59]. - CooperSurgical (CSI) revenue for Q4 was $355.6 million, up 4% year-over-year, with organic growth also at 4% [12][59]. Margins and Costs - Gross margin for Q4 was 61%, down from 67% in the previous year, primarily due to reorganization costs [6][13]. - Non-GAAP gross margin was 66%, down 70 basis points from last year [6][13]. - Operating margin for Q4 was 13%, compared to 19% in the previous year, while non-GAAP operating margin improved to 27% [6][13]. Cash Flow and Share Repurchase - Cash provided by operations was $247.8 million, leading to free cash flow of $149.8 million after capital expenditures of $98.0 million [6][13]. - The company repurchased $197.3 million of common stock in Q4 and $290.1 million for the fiscal year, with a total share repurchase authorization of $2 billion [13][14]. Future Guidance - For fiscal year 2026, the company expects total revenue between $4.299 billion and $4.338 billion, with organic growth of 4.5% to 5.5% [20]. - Non-GAAP diluted EPS guidance for fiscal 2026 is projected to be between $4.45 and $4.60 [20].